AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the ...
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe ...
Investor's Business Daily on MSN6h
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment
AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.
FierceBiotech6h
AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in phase 2 trial
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
AnaptysBio Shares Surge 37% After Mid-Stage Rheumatoid Arthritis Trial Meets Primary Goal
AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.
Anaptys surges as arthritis therapy succeeds in mid-stage trial
AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...
Biolog Purchases Anaerobe Systems, Its Third Acquisition, Becoming the Knowledge Leader in Microbiology Research and Clinical Sample Prep
Biolog, Inc., a leading provider of cell-based microbial and phenotypic profiling products and multiomic microbial identification services, today announced the acquisition of Anaerobe Systems, Inc.